


Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application.

1. (canceled)

2. (currently amended) A process for extracting 5-O-methyl-*myo*-inositol from *Taxus spp*, said process comprising: (a) extracting *Taxus spp* with an organic solvent to obtain an extractum,
(b) subjecting the extractum to a diphasic extraction,
(c) subjecting the water layers of said diphasic extraction to chromatography using a macroporous resin column, and collecting fractions containing 5-O-methyl-*myo*-inositol, then
(d) concentrating, crystallizing, and filtering to obtain a powder, recrystallizing the powder to obtain a second powder in which more than 90% of the second powder is said 5-O-methyl-*myo*-inositol wherein said 5-O-methyl-*myo*-inositol has formula I:



wherein the organic solvent used for extraction is selected from the group consisting of ethanol, methanol, acetone, and aqueous mixtures thereof, and the solvent used for diphasic extraction is a water insoluble organic solvent.

3. (previously presented) The method according to claim 2, characterized in that said *Taxus spp* is *Taxus yunnanensis* Cheng et L. K. Fu, or *Taxus chinensis* var. *mairei* (Lemee et Levl) Cheng et L. K. Fu.

4. - 5. (canceled)


6. (currently amended) The method according to claim 2, characterized in that the solvent used for diphasic extraction is selected from the group consisting of ethyl acetate, chloroform, dichloromethane and ethyl ether.

7. (canceled)

8. (currently amended) The method according to claim 2, characterized in that the solvent system used for recrystallization is a solvent system selected from the group consisting of ethanol, methanol, acetone, methylethylketone and a mixture thereof.

9. - 10. (canceled)

11. (previously presented) A method for treatment of a disease related to diabetes comprising administering to a patient in need thereof a medicament that contains extracted natural compound 5-O-methyl-*myo*-inositol having the formula I:



wherein said disease related to diabetes is selected from the group consisting of diabetic cardiovascular, cerebrovessel and glycometabolic disorder-associated diseases.

12. (previously presented) The method according to claim 11, characterized in that said medicament alleviates the hyperglycemia of diabetes, inhibits the decomposition of hepatic glycogen and the absorption of glucose, reduces the blood fat level, and protects the β cells of the pancreatic island in said patient.

13. (previously presented) The method according to claim 11, wherein said method treats complications from diabetic cardiovascular and other glycometabolic disorder-associated diseases in said patient.

14. (previously presented) The method according to claim 11, wherein said method treats type-II diabetes and complications in terms of diabetic cardiovascular in said patient.

15.-18. (canceled)